Published in Pain on December 11, 2013
Botulinum Toxin for Neuropathic Pain: A Review of the Literature. Toxins (Basel) (2015) 0.93
Therapeutic use of botulinum toxin in migraine: mechanisms of action. Br J Pharmacol (2014) 0.88
The search for novel analgesics: targets and mechanisms. F1000Prime Rep (2015) 0.79
Botulinum toxin in migraine: Role of transport in trigemino-somatic and trigemino-vascular afferents. Neurobiol Dis (2015) 0.77
Current Status and Future Directions of Botulinum Neurotoxins for Targeting Pain Processing. Toxins (Basel) (2015) 0.77
Incobotulinum Toxin-A Improves Post-Surgical and Post-Radiation Pain in Cancer Patients. Toxins (Basel) (2016) 0.76
Effects of intraplantar botulinum toxin-B on carrageenan-induced changes in nociception and spinal phosphorylation of GluA1 and Akt. Eur J Neurosci (2016) 0.75
Is BoNT/B useful for pain treatment? Pain (2014) 0.75
The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature (1997) 30.59
Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature (1992) 8.39
Molecular mechanisms of nociception. Nature (2001) 7.75
Neurotoxins affecting neuroexocytosis. Physiol Rev (2000) 5.42
TRPA1 mediates formalin-induced pain. Proc Natl Acad Sci U S A (2007) 5.27
OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache (2010) 4.37
OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia (2010) 4.24
Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science (1997) 4.03
An open study of botulinum-A toxin treatment of trigeminal neuralgia. Neurology (2005) 2.91
Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann Neurol (2008) 2.81
Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology (2009) 2.63
Transmission of chronic nociception by spinal neurons expressing the substance P receptor. Science (1999) 2.43
Two vesicle-associated membrane protein genes are differentially expressed in the rat central nervous system. J Biol Chem (1989) 2.23
Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo. Nature (1980) 2.08
Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science (1992) 2.00
How botulinum and tetanus neurotoxins block neurotransmitter release. Biochimie (2000) 1.90
Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli. J Neurosci Methods (1997) 1.82
An automated flinch detecting system for use in the formalin nociceptive bioassay. J Appl Physiol (1985) (2001) 1.68
Long-distance retrograde effects of botulinum neurotoxin A. J Neurosci (2008) 1.66
Botulinal neurotoxins: revival of an old killer. Curr Opin Pharmacol (2005) 1.66
Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain (2004) 1.65
Fos, nociception and the dorsal horn. Prog Neurobiol (2005) 1.65
Response properties of mechanoreceptors and nociceptors in mouse glabrous skin: an in vivo study. J Neurophysiol (2001) 1.62
Subcutaneous injection of botulinum toxin a is beneficial in postherpetic neuralgia. Pain Med (2010) 1.61
Intrathecal substance P elicits a caudally-directed biting and scratching behavior in mice. Brain Res (1981) 1.61
Capsaicin receptor: TRPV1 a promiscuous TRP channel. Handb Exp Pharmacol (2007) 1.56
Potentiation of tachykinin-induced plasma protein extravasation by calcitonin gene-related peptide. Eur J Pharmacol (1985) 1.56
Efficacy of spinal NMDA receptor antagonism in formalin hyperalgesia and nerve injury evoked allodynia in the rat. J Pharmacol Exp Ther (1997) 1.50
Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci (2007) 1.48
Botulinum toxin type A reduces histamine-induced itch and vasomotor responses in human skin. Br J Dermatol (2009) 1.45
The concept of neurogenic inflammation. BJU Int (2008) 1.41
Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience (2011) 1.29
Inhibition by spinal mu- and delta-opioid agonists of afferent-evoked substance P release. J Neurosci (2005) 1.27
The journey of tetanus and botulinum neurotoxins in neurons. Trends Microbiol (2003) 1.23
Distinct patterns of expression of two VAMP genes within the rat brain. J Neurosci (1990) 1.22
Nociception and TRP Channels. Curr Drug Targets CNS Neurol Disord (2004) 1.20
The types of neuron in spinal dorsal horn which possess neurokinin-1 receptors. Neuroscience (1995) 1.19
Morphological characterization of substance P receptor-immunoreactive neurons in the rat spinal cord and trigeminal nucleus caudalis. J Comp Neurol (1995) 1.19
Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol (2000) 1.18
Differential activation of trigeminal C or Adelta nociceptors by infrared diode laser in rats: behavioral evidence. Brain Res (2005) 1.16
Relationship between capsaicin-evoked substance P release and neurokinin 1 receptor internalization in the rat spinal cord. Neuroscience (2003) 1.15
Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology (2001) 1.11
Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci (2011) 1.11
A plethora of presynaptic proteins associated with ATP-storing organelles in cultured astrocytes. Glia (1999) 1.11
Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci (2002) 1.10
Anatomy of primary afferents and projection neurones in the rat spinal dorsal horn with particular emphasis on substance P and the neurokinin 1 receptor. Exp Physiol (2002) 1.09
The upright posture improves plantar stepping and alters responses to serotonergic drugs in spinal rats. J Physiol (2012) 1.07
Stereospecific effects of a nonpeptidic NK1 selective antagonist, CP-96,345: antinociception in the absence of motor dysfunction. Life Sci (1991) 1.06
Neurogenic inflammation. A model for studying efferent actions of sensory nerves. Adv Exp Med Biol (1996) 1.06
Central origin of the antinociceptive action of botulinum toxin type A. Pharmacol Biochem Behav (2009) 1.06
The life history of a botulinum toxin molecule. Toxicon (2013) 1.05
Transsynaptic inhibition of spinal transmission by A2 botulinum toxin. J Physiol (2012) 1.01
Botulinum toxin's axonal transport from periphery to the spinal cord. Neurochem Int (2012) 1.01
NK-1 receptor mediation of neurogenic plasma extravasation in rat skin. Br J Pharmacol (1989) 1.00
Botulinum neurotoxins A and E undergo retrograde axonal transport in primary motor neurons. PLoS Pathog (2012) 1.00
Botulinum neurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon (2002) 1.00
Beyond muscular effects: depression of spinal recurrent inhibition after botulinum neurotoxin A. J Physiol (2012) 1.00
The analgesic effect on neuropathic pain of retrogradely transported botulinum neurotoxin A involves Schwann cells and astrocytes. PLoS One (2012) 1.00
Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skin. Pain (2008) 0.99
Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: bilateral effect after unilateral injection. Eur J Pharmacol (2010) 0.99
Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol (2003) 0.98
Antinociceptive effect of botulinum toxin type a in rat model of carrageenan and capsaicin induced pain. Croat Med J (2005) 0.97
Tetanus toxin and botulinum toxin a utilize unique mechanisms to enter neurons of the central nervous system. Infect Immun (2012) 0.97
Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport. Traffic (2012) 0.95
Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering. Toxins (Basel) (2010) 0.95
Spinal N-methyl-D-aspartate receptors and nociception-evoked release of primary afferent substance P. Neuroscience (2008) 0.94
Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. Pain (2010) 0.94
Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain. Neuroscience (2007) 0.94
Neurotherapeutics to inhibit exocytosis from sensory neurons for the control of chronic pain. Curr Opin Pharmacol (2011) 0.93
Type A1 but not type A2 botulinum toxin decreases the grip strength of the contralateral foreleg through axonal transport from the toxin-treated foreleg of rats. J Pharmacol Sci (2011) 0.92
Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators. FEBS J (2011) 0.92
Botulinum toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain (2006) 0.92
Aberrant sensory responses are dependent on lesion severity after spinal cord contusion injury in mice. Pain (2009) 0.92
Tachykinins and calcitonin gene-related peptide enhance release of endogenous glutamate and aspartate from the rat spinal dorsal horn slice. J Neurosci (1990) 0.92
The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can J Anaesth (2006) 0.91
The actions of capsaicin applied topically to the skin of the rat on C-fibre afferents, antidromic vasodilatation and substance P levels. Br J Pharmacol (1992) 0.91
The effects of substance P and calcitonin gene-related peptide on the efflux of endogenous glutamate and aspartate from the rat spinal dorsal horn in vitro. Neurosci Lett (1990) 0.90
Extravesicular intraneuronal migration of internalized botulinum neurotoxins without detectable inhibition of distal neurotransmission. Biochem J (2012) 0.90
A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology (2003) 0.90
Small sensory neurons in the rat dorsal root ganglia express functional NK-1 tachykinin receptor. Eur J Neurosci (1998) 0.89
Botulinum neurotoxins and formalin-induced pain: central vs. peripheral effects in mice. Brain Res (2006) 0.87
Expression of tachykinin NK1 receptor mRNA in dorsal root ganglia of the mouse. Brain Res Mol Brain Res (1996) 0.87
Lack of anti-inflammatory effect of botulinum toxin type A in experimental models of inflammation. Fundam Clin Pharmacol (2008) 0.87
Growth of the corticospinal tract and the development of placing reactions in the postnatal rat. J Comp Neurol (1977) 0.86
Regulation of spinal substance p release by intrathecal calcium channel blockade. Anesthesiology (2011) 0.86
Botulinum neurotoxin type A counteracts neuropathic pain and facilitates functional recovery after peripheral nerve injury in animal models. Neuroscience (2010) 0.84
Effect of the tachykinin NK1 receptor antagonists, RP 67580 and SR 140333, on electrically-evoked substance P release from rat spinal cord. Br J Pharmacol (1994) 0.84
Botulinum toxin A increases analgesic effects of morphine, counters development of morphine tolerance and modulates glia activation and μ opioid receptor expression in neuropathic mice. Brain Behav Immun (2013) 0.84
Action of intrathecal capsaicin and its structural analogues on the content and release of spinal substance P: selectivity of action and relationship to analgesia. Brain Res (1984) 0.84
Involvement of μ-opioid receptors in antinociceptive action of botulinum toxin type A. Neuropharmacology (2013) 0.84
Botulinum toxin type A reduces hyperalgesia and TRPV1 expression in rats with neuropathic pain. Pain Med (2013) 0.84
Lack of evidence for the size principle of selective vulnerability of axons in toxic neuropathies. I. The effects of subcutaneous injections of 2,5-hexanedione on behavior and muscle spindle function. Toxicol Appl Pharmacol (1990) 0.84
Activation of neurokinin-1 receptors increases the excitability of guinea pig dorsal root ganglion cells. J Pharmacol Exp Ther (2012) 0.83
Spinal botulinum neurotoxin B: effects on afferent transmitter release and nociceptive processing. PLoS One (2011) 0.83
Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med (2006) 0.83
Basal and activity-induced release of substance P from primary afferent fibres in NK1 receptor knockout mice: evidence for negative feedback. Neuropharmacology (2003) 0.83
Localization of the neurokinin 1 receptor on a subset of substance P-positive and isolectin B4-negative dorsal root ganglion neurons of the rat. Neurosci Lett (1999) 0.81
Single application of A2 NTX, a botulinum toxin A2 subunit, prevents chronic pain over long periods in both diabetic and spinal cord injury-induced neuropathic pain models. J Pharmacol Sci (2012) 0.81
Spinal neurokinin NK1 receptor down-regulation and antinociception: effects of spinal NK1 receptor antisense oligonucleotides and NK1 receptor occupancy. J Neurochem (1998) 0.81
[Botulinum toxin type A in the treatment of neuropathic pain in a case of postherpetic neuralgia]. Neurologia (2008) 0.81